Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer

S. Ishikawa, M. S. Soloway, R. Van Der Zwaag, B. Todd

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

We analyzed 110 patients with metastatic prostate cancer (stage D2) to determine the associations between interval until progression and the pretreatment testosterone level, extent of bone metastases, performance status, race, age and pretreatment level of prostatic acid phosphatase. The median followup was 21 months (4 to 89 months). All patients received androgen deprivation therapy when metastases were identified. This multivariate analysis demonstrated that the pretreatment serum testosterone was the most significant variable (p less than 0.01) associated with interval until progression and the extent of bone metastases observed on the bone scan was the second most important variable (p less than 0.05). Age, race and prostatic acid phosphatase were not significantly correlated with the interval free of progression. Performance status was significantly correlated but it was nonsignificant in the multivariate analysis if the model already included testosterone level and extent of metastasis. Patients with a pretreatment testosterone level of less than 300 ng. per 100 ml. and more than 6 areas of increased uptake on the bone scan had the most rapid progression. We conclude that serum testosterone and extent of bone metastases are the most important of the analyzed factors in terms of interval to progression in patients with prostate cancer following androgen deprivation.

Original languageEnglish
Pages (from-to)1139-1142
Number of pages4
JournalJournal of Urology
Volume141
Issue number5
StatePublished - Jan 1 1989
Externally publishedYes

Fingerprint

Androgens
Disease-Free Survival
Testosterone
Prostatic Neoplasms
Neoplasm Metastasis
Bone and Bones
Multivariate Analysis
Therapeutics
Serum
prostatic acid phosphatase

ASJC Scopus subject areas

  • Urology

Cite this

Ishikawa, S., Soloway, M. S., Van Der Zwaag, R., & Todd, B. (1989). Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. Journal of Urology, 141(5), 1139-1142.

Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. / Ishikawa, S.; Soloway, M. S.; Van Der Zwaag, R.; Todd, B.

In: Journal of Urology, Vol. 141, No. 5, 01.01.1989, p. 1139-1142.

Research output: Contribution to journalArticle

Ishikawa, S, Soloway, MS, Van Der Zwaag, R & Todd, B 1989, 'Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer', Journal of Urology, vol. 141, no. 5, pp. 1139-1142.
Ishikawa, S. ; Soloway, M. S. ; Van Der Zwaag, R. ; Todd, B. / Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. In: Journal of Urology. 1989 ; Vol. 141, No. 5. pp. 1139-1142.
@article{9464316b5dc34a0fba8c552c280c6562,
title = "Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer",
abstract = "We analyzed 110 patients with metastatic prostate cancer (stage D2) to determine the associations between interval until progression and the pretreatment testosterone level, extent of bone metastases, performance status, race, age and pretreatment level of prostatic acid phosphatase. The median followup was 21 months (4 to 89 months). All patients received androgen deprivation therapy when metastases were identified. This multivariate analysis demonstrated that the pretreatment serum testosterone was the most significant variable (p less than 0.01) associated with interval until progression and the extent of bone metastases observed on the bone scan was the second most important variable (p less than 0.05). Age, race and prostatic acid phosphatase were not significantly correlated with the interval free of progression. Performance status was significantly correlated but it was nonsignificant in the multivariate analysis if the model already included testosterone level and extent of metastasis. Patients with a pretreatment testosterone level of less than 300 ng. per 100 ml. and more than 6 areas of increased uptake on the bone scan had the most rapid progression. We conclude that serum testosterone and extent of bone metastases are the most important of the analyzed factors in terms of interval to progression in patients with prostate cancer following androgen deprivation.",
author = "S. Ishikawa and Soloway, {M. S.} and {Van Der Zwaag}, R. and B. Todd",
year = "1989",
month = "1",
day = "1",
language = "English",
volume = "141",
pages = "1139--1142",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer

AU - Ishikawa, S.

AU - Soloway, M. S.

AU - Van Der Zwaag, R.

AU - Todd, B.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - We analyzed 110 patients with metastatic prostate cancer (stage D2) to determine the associations between interval until progression and the pretreatment testosterone level, extent of bone metastases, performance status, race, age and pretreatment level of prostatic acid phosphatase. The median followup was 21 months (4 to 89 months). All patients received androgen deprivation therapy when metastases were identified. This multivariate analysis demonstrated that the pretreatment serum testosterone was the most significant variable (p less than 0.01) associated with interval until progression and the extent of bone metastases observed on the bone scan was the second most important variable (p less than 0.05). Age, race and prostatic acid phosphatase were not significantly correlated with the interval free of progression. Performance status was significantly correlated but it was nonsignificant in the multivariate analysis if the model already included testosterone level and extent of metastasis. Patients with a pretreatment testosterone level of less than 300 ng. per 100 ml. and more than 6 areas of increased uptake on the bone scan had the most rapid progression. We conclude that serum testosterone and extent of bone metastases are the most important of the analyzed factors in terms of interval to progression in patients with prostate cancer following androgen deprivation.

AB - We analyzed 110 patients with metastatic prostate cancer (stage D2) to determine the associations between interval until progression and the pretreatment testosterone level, extent of bone metastases, performance status, race, age and pretreatment level of prostatic acid phosphatase. The median followup was 21 months (4 to 89 months). All patients received androgen deprivation therapy when metastases were identified. This multivariate analysis demonstrated that the pretreatment serum testosterone was the most significant variable (p less than 0.01) associated with interval until progression and the extent of bone metastases observed on the bone scan was the second most important variable (p less than 0.05). Age, race and prostatic acid phosphatase were not significantly correlated with the interval free of progression. Performance status was significantly correlated but it was nonsignificant in the multivariate analysis if the model already included testosterone level and extent of metastasis. Patients with a pretreatment testosterone level of less than 300 ng. per 100 ml. and more than 6 areas of increased uptake on the bone scan had the most rapid progression. We conclude that serum testosterone and extent of bone metastases are the most important of the analyzed factors in terms of interval to progression in patients with prostate cancer following androgen deprivation.

UR - http://www.scopus.com/inward/record.url?scp=0024563394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024563394&partnerID=8YFLogxK

M3 - Article

C2 - 2651713

AN - SCOPUS:0024563394

VL - 141

SP - 1139

EP - 1142

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -